Description du projet
Détecter la septicémie en moins d’une demi-heure – un appareil de détection unique
La septicémie constitue un problème de santé mondial et sa détection précoce, dès son origine, est cruciale pour la survie. Pour contribuer au diagnostic rapide de la septicémie, le projet IVD4Sepsis, financé par l’UE, a mis au point un équipement ultrasensible capable de détecter simultanément 30 biomarqueurs associés à la septicémie pour une fraction du coût des autres technologies existantes. Le diagnostic prend moins de 20 minutes et la sensibilité est un million de fois plus élevée que les méthodes actuelles utilisées en clinique. Compte tenu du nombre élevé de décès associés à la septicémie, le dispositif IVD4Sepsis a le potentiel d’améliorer l’issue de la maladie en offrant un diagnostic rapide et ultrasensible.
Objectif
More than 27 M people per year develop sepsis, which has been catalogued as a Global health problem & priority. Sepsis kills more people than AIDs, prostate and breast cancer combined globally, and it lack of appropriate diagnostic tools. Moreover it has been demonstrated that early detection during the first hours is crucial for survival.
Mecwins has developed the AVAC Technology prototype, an ultrasensitive detection equipment for early detection of sepsis, with: i) sensitivity a million times higher than current levels in clinical practice, ii) requiring smaller biological sample for the test, iii) multiplexing capability 30 biomarkers per analysis, iv) less diagnosis time ≤20 min, v) scalable solution - reference technology applicable to a wide range of other clinical applications (oncology, cardiovascular, autoimmune diseases, etc.).
The unique value proposition of AVAC Technology is based on the early, accurate and fast diagnosis of sepsis and its competitive price (30€ per test versus 150€ per test with PCR-Roche) compared to current techniques (PCR & ELISA).
Sepsis market is included on the infectious market and it was worth 278 M€ in 2015. Some estimations claim that it will grow until 717 M€ in 2021. Mecwins foresees to reach 25% of the total market by 2027 IVD4Sepsis through a double one-off revenue business model, and expecting a turnover accounting for almost 42,5 M€ by 2025.
Champ scientifique
- medical and health scienceshealth sciencespublic health
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
15707 SANTIAGO DE COMPOSTELA
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.